Expert Insights from Dr. Prof. Uday C. Ghoshal on Constipation Care for Elderly and Comorbid Patients, Chronic constipation, Elobixibat, General Practitioner, Consultant Physician, General Practice, Constipation Management, Gastroenterology, Gastroenterologist, Consultant Physician, SBM: Spontaneous Bowel Movement, CSBM: Complete Spontaneous Bowel Movement
This article is brought to you by Bixibat
This Article is brought to you by BixiBat
The study evaluated safety outcomes in 1,049 patients and efficacy outcomes in 986 patients based on patient interviews. In individuals aged 65+ and 75+, there was a significant improvement in weekly bowel movements and mean Bristol Stool Form Scale (BSFS) scores compared to baseline.3
Elobixibat was well tolerated among elderly patients with chronic constipation. The ADRs were reported by only 4.46% of patients aged 65 years and older and 3.58% of patients aged 75 years and older.3
Elobixibat is found to have good safety in patients with chronic constipation who have renal disease, heart disease, and diabetes.4,6-9 Elobixibat is effective and well tolerated in elderly and comorbid patients with chronic constipation.1,2,5-8
Let’s hear to what Dr. Omesh Goyal and Dr. Uday Chand Ghoshal have to say about the use of Elobixibat in elderly and comorbid patients.
 |
ConclusionElobixibat stands out as a safe and effective treatment for chronic constipation, particularly in elderly and comorbid patients. The drug’s localized action minimizes systemic absorption, reducing the risk of adverse drug reactions and drug interactions. Its tolerability in patients with complex conditions such as renal, cardiac, and diabetes further highlights its utility in clinical practice. Elobixibat offers a reliable, patient-friendly solution for managing chronic constipation with enhanced safety and efficacy. |
CI: Confidence interval; CSBM: Complete spontaneous bowel movement; MoM: Milk of magnesia; n/a: Not available; NNT: Number needed to treat; NSAID: Nonsteroidal anti-inflammatory drug; PEG: Polyethylene glycol; SBM: Spontaneous bowel movement.
References: 1. GOOFICE® (elobixibat hydrate tablet). Available at: https://www.eapharma.co.jp/sites/default/files/corporate_files/en_products_details/pdf/goofice/ GOF_TB_202012_EN.pdf. Accessed on: 16 June 2024. 2. Chedid V, Vijayvargiya P, Camilleri M. Elobixibat for the treatment of constipation. Expert Rev Gastroenterol Hepatol. 2018;12(10):951–960. 3. Nakajima A, Fujimaki M, Arai Y, et al. Safety and efficacy of elobixibat, an ileal bile acid transporter inhibitor, in elderly patients with chronic idiopathic constipation according to administration time: Interim analysis of post-marketing surveillance. J Neurogastroenterol Motil. 2022;28(3):431–441. 4. Matsuyama M, Hirai K, Nonaka H, et al. Effects of elobixibat on constipation and lipid metabolism in patients with moderate to end-stage chronic kidney disease. Front Med (Lausanne). 2022;8:780127. 5. Misawa N, Higurashi T, Takatsu T, et al. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota. Aliment Pharmacol Ther. 2020;52(5):821–828. 6. Hishida Y, Nagai Y, Tsukiyama H, et al. Effects of elobixibat in patients with diabetes and concomitant chronic constipation: An 8-week, prospective, single-center, single-arm study. Adv Ther. 2022;39(9):4205–4217. 7. Fujisue K, Ito M, Matsuzawa Y, et al. Open-label, single-center, single-arm study evaluating the efficacy and safety of elobixibat for chronic constipation in patients with heart failure. Circ Rep. 2024;6(3):55–63. 8. Ozaki A, Kessoku T, Kasai Y, et al. Elobixibat effectively relieves chronic constipation in patients with cancer regardless of the amount of food intake. Oncologist. 2021;26(10):e1862–e1869. 9. Hatano T, Oyama G, Shimo Y, et al. Efficacy and safety of elobixibat in Parkinson’s disease with chronic constipation: CONST-PD Study. Mov Disord Clin Pract. 2024;11(4):352–362.
For the use of a Registered Medical Practitioner, Hospital or a Laboratory only. GGI-CO-A1-AQS-300041570-ELC-L24-0760
